RecruitingSolid Tumors

A Study of ZL-1310 in Participants With Selected Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

9 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Sponsor: Zai Lab (Shanghai) Co., Ltd.

✓ Signed informed consent
✓ Adult men and women ≥18 years of age
✓ Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC)
✓ Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample
✓ Participants must have at least one measurable target lesion as defined by RECIST v1.1
✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
✓ Life expectancy ≥ 3 months

✕ Participants with another known malignancy that is progressing or requires active treatment within the last 2 years
✕ Clinically active central nervous system (CNS) metastases
✕ Participants with leptomeningeal metastasis
✕ Participants who have received any ADC with a payload of topoisomerase I inhibitor (e.g., exatecan derivative)or had received topoisomerase I inhibitor (e.g., irinotecan) as the immediate prior therapy that the participant had progressed from.
✕ Treatment with any systemic anti-cancer treatment or other investigational products/device within 3 weeks before the first dose of study treatment
✕ Non-palliative radiotherapy within 2 weeks to non-thoracic area or within 4 weeks to the thoracic area prior to first dose of study treatment or a history of radiation pneumonitis
✕ Major surgery within 4 weeks of the first dose of study treatment
✕ Hypersensitivity to any ingredient of the study treatment

San Francisco

Peoria

Detroit

Cleveland

Philadelphia

Nashville

Dallas · Houston · McAllen

Fairfax · Norfolk

Source: ClinicalTrials.gov · NCT06885281 · last updated 2026-08-21